Experienced in Sideroblastic Anemia

Dr. Madhuri Vusirikala

Hematology Oncology | Transplant Surgery
5323 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 2 Trials
27 Years of Experience
Experienced in Sideroblastic Anemia
5323 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Madhuri Vusirikala is a Hematologist Oncology specialist and a Transplant Surgeon in Dallas, Texas. Dr. Vusirikala has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of Sideroblastic Anemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5323 Harry Hines Blvd, Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
Enrollment Status: Terminated
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

21 Total Publications

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Journal: Leukemia
Published: October 31, 2024
Similar Doctors
Advanced in Sideroblastic Anemia
Dr. Amanullah D. Khan
Hematology Oncology | Oncology
Advanced in Sideroblastic Anemia
Dr. Amanullah D. Khan
Hematology Oncology | Oncology
4201 Medical Center Dr, Suite 180, 
Mckinney, TX 
 (26.9 miles away)
214-424-3615
Languages Spoken:
English, Estonian, Hindi, Spanish, Tamil, Urdu
See accepted insurances
Accepting New Patients

Amanullah Khan is a Hematologist Oncology specialist and an Oncologist in Mckinney, Texas. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Gallbladder Adenocarcinoma. Dr. Khan is currently accepting new patients.

Advanced in Sideroblastic Anemia
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology
Advanced in Sideroblastic Anemia
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology

Texas Oncology PA

4215 Joe Ramsey Blvd, 
Greenville, TX 
 (46.7 miles away)
903-408-5112
Languages Spoken:
English, French, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Meera Shreedhara-Vasudha is an Oncologist and a Hematologist Oncology provider in Greenville, Texas. Dr. Shreedhara-Vasudha is rated as a Distinguished provider by MediFind in the treatment of Sideroblastic Anemia. Her top areas of expertise are Leukocytosis, Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, and Paget Disease of the Breast. Dr. Shreedhara-Vasudha is currently accepting new patients.

Experienced in Sideroblastic Anemia
Dr. Ajit M. Dave
Hematology Oncology | Hematology | Oncology
Experienced in Sideroblastic Anemia
Dr. Ajit M. Dave
Hematology Oncology | Hematology | Oncology
3327 Colorado Blvd, Suite 200, 
Denton, TX 
 (29.3 miles away)
940-382-4060
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Ajit Dave is a Hematologist Oncology specialist and a Hematologist in Denton, Texas. Dr. Dave is rated as an Experienced provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Acute Eosinophilic Pneumonia, Hypereosinophilic Syndrome, Idiopathic Neutropenia, and Sideroblastic Anemia. Dr. Dave is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vusirikala's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 20 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile